10/19/2023 | CV | Market Commentary: Enovis convertible offering eyed; Semtech launches, pulls placement; Rivian falls
|
9/18/2023 | CV | Market Commentary: NIO convertible offering on deck; Duke active; PTC Therapeutics decline continues
|
9/18/2023 | CV | Market Commentary: Morning Commentary: Seagate exchangeables weaken; PTC Therapeutics downfall continues
|
5/24/2023 | CV | Market Commentary: Duke, CMS, Welltower hit new lows; Sarepta, PTC Therapeutics down outright, up on swap
|
9/20/2019 | CV | PTC Therapeutics greenshoe ups 1.5% convertibles to $287.5 million
|
9/20/2019 | CV | Market Commentary: Upsized SailPoint convertibles slip below par in secondary action; RWT adds with shares
|
9/18/2019 | CV | Market Commentary: Etsy, SailPoint deals join primary calendar as Fed cuts rates; new PTC Therapeutics adds
|
9/18/2019 | CV | Market Commentary: Morning Commentary: PTC Therapeutics convertible weighed by stock drop; Adesto eyed
|
9/18/2019 | CV | New Issue: PTC Therapeutics prices $250 million 1.5% seven-year convertible notes, up 30%
|
9/17/2019 | CV | Market Commentary: PTC Therapeutics, Adesto, Ubisoft pricing convertibles; trading light amid Fed meeting
|
9/17/2019 | CV | PTC Therapeutics talks $250 million seven-year convertibles to yield 1%-1.5%, up 30%-35%
|
6/19/2018 | CV | Market Commentary: Sarepta convertibles skyrocket; PTC Therapeutics drops; Canopy gains; Sea, Twitter active
|
6/18/2018 | CV | Market Commentary: Canopy Growth convertibles in demand; PTC Therapeutics jumps; Teladoc in the money
|
6/18/2018 | CV | Market Commentary: Morning Commentary: Canopy Growth convertibles maintain strength; PTC Therapeutics jumps
|
9/28/2017 | CV | Market Commentary: Western Asset prices cheap; DexCom steals the show as convertibles drop; PTC in focus
|
3/2/2017 | CV | Market Commentary: Lumentum deal added to convertibles calendar; Viavi fades; PTC drops on clinical trial news
|
10/17/2016 | CV | Market Commentary: Health care convertibles in focus, weaker; Take-Two jumps outright on game chatter
|
9/19/2016 | CV | Market Commentary: Convertibles quiet; Blackhawk drags outright, dollar neutral; PTC Therapeutics moves up
|
9/19/2016 | CV | Market Commentary: Morning Commentary: DepoMed’s convertibles trade just under 140; PTC Therapeutics poised to move up
|
4/15/2016 | CV | Market Commentary: PTC Therapeutics up on regulatory nod; market quiet; response to energy bankruptcies muted
|
2/24/2016 | CV | Market Commentary: Chesapeake gains on debt buyback news; WebMD jumps after guiding Q1 revenue upward
|
2/23/2016 | CV | Market Commentary: PTC Therapeutics collapses; SanDisk steady after lowered deal price; Stone Energy drops
|
11/20/2015 | CV | Market Commentary: Morning Commentary: BioMarin bonds, stock drop as FDA criticizes drug; biotech wanes in sympathy
|
11/19/2015 | CV | Market Commentary: Chesapeake Energy gaps down; AMAG continues trajectory lower; Vodafone prices £600 million
|
10/19/2015 | CV | Market Commentary: PTC Therapeutics drops; Immunomedics adds about 3 points; Campus Crest trades around par
|
10/16/2015 | CV | Market Commentary: Convertibles mostly quiet; PTC Therapeutics little changed after trial news; SolarCity, Greenbrier shares down
|
10/16/2015 | CV | Market Commentary: Morning Commentary: PTC Therapeutics little changed after trial news; overall trading quiet
|
8/17/2015 | CV | Market Commentary: Light volume mutes trends; Micron, Chesapeake trade weakly; PTC pops; SunEdison launches convert
|
8/14/2015 | CV | PTC Therapeutics greenshoe lifts 3% convertible sale to $150 million
|
8/11/2015 | CV | Market Commentary: Convertibles weaken; SunEdison, Tesla Motors down; PTC Therapeutics pulls off solid debut
|
8/11/2015 | CV | Market Commentary: Morning Commentary: New PTC Therapeutics holds up against weaker shares; Exelixis shares slip
|
8/11/2015 | CV | New Issue: PTC Therapeutics prices $125 million seven-year convertibles to yield 3%, up 30%
|
8/10/2015 | CV | Market Commentary: Whiting Petroleum improves; Iconix 2.5% convertibles claw back; Impax slips; PTC to price
|
8/10/2015 | CV | PTC Therapeutics plans $125 million seven-year convertibles to yield 2.5%-3%, up 30%-35%
|